BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK signaling cascade, a signal transduction pathway that transmits mitogenic ...

One of the standard treatment options for melanoma over the last 10 years has been to simultaneously target both BRAF ...

Building on this research, Professors Marshall and Richard Marais – who at the time was a colleague at the ICR – conducted further experiments on the pathway. They predicted that a protein called BRAF ...

On Thursday, Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced safety, tolerability, pharmacokinetic (PK), and preliminary ...

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

but also sensitizes the tumors to specific inhibitors of pathway components. As we have reported, the BRAF and RAS mutant tumors are more sensitive to ERK pathway inhibition than the RAF/RAS wild type ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

One of the standard treatment options for melanoma over the last ten years has been to simultaneously target both BRAF ...

Excess number of genetic copies may be a factor in triggering growth of cancer cells, scientists at the German Cancer Research Center, Heidelberg, have revealed. New data, generated by Peter ...